Neutral On Biogen Daily Markets (blog) Other interesting candidates in the MS pipeline daclizumab, which is being developed in collaboration with Abbott Labs (NYSE:ABT), and PEGylated interferon. Biogen's pipeline also has candidates for other ailments like amyotrophic lateral sclerosis ... |
